Evgen Pharma PLC Director dealing (3213R)
March 05 2021 - 3:17AM
UK Regulatory
TIDMEVG
RNS Number : 3213R
Evgen Pharma PLC
05 March 2021
5 March 2021
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Director dealing
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company, has been notified that Richard Moulson, Chief Financial
Officer of the Company, has purchased 3,787 ordinary shares of 0.25
pence each in the capital of the Company ("Ordinary Shares") at a
purchase price of 8 pence per Ordinary Share, as part of the Open
Offer in the recent Fundraise. Following this purchase, Richard
Moulson holds a total of 45,454 Ordinary Shares, representing
approximately 0.02 per cent. of the Company's issued share
capital.
Enquiries:
Evgen Pharma plc Via Walbrook
Barry Clare, Chairman
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane / Sunila de Silva
(ECM)
www.finncap.com +44 (0) 20 7220 0500
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
Paul McManus/ Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876
741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
Accordingly, the Company makes the following announcement and
notification in accordance with the EU Market Abuse Regulation (No
596/2014):
1. Details of Persons Discharging Managerial Responsibilities
"PDMR" / person closely associated with them ('PCA')
==================================================================================
a) Name Richard Moulson
================================ ================================================
2. Reason for notification
==================================================================================
b) Position / status CFO
================================ ================================================
c) Initial notification / amendment Initial Notification
================================ ================================================
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==================================================================================
b) Name Evgen Pharma plc
================================ ================================================
c) LEI 213800NO3E6TSTQO8K20
================================ ================================================
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
==================================================================================
a) Description of the financial ordinary shares of 0.25p each
instrument
Identification code GB00BSVYN304
================================ ================================================
b) Nature of the transaction Acquisition of shares pursuant to the Open Offer
================================ ================================================
c) Price(s) and volume(s) Price(s) Volume(s)
GBP0.08 3,787
----------
================================ ================================================
d) Aggregated information As above
Aggregated volume Price
================================ ================================================
e) Date of the transaction 3 March 2021
================================ ================================================
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
================================ ================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDKPBDCBKKPNK
(END) Dow Jones Newswires
March 05, 2021 04:17 ET (09:17 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024
